[go: up one dir, main page]

WO2006036465A3 - Compositions et methodes de traitement de la fibrose kystique - Google Patents

Compositions et methodes de traitement de la fibrose kystique Download PDF

Info

Publication number
WO2006036465A3
WO2006036465A3 PCT/US2005/031576 US2005031576W WO2006036465A3 WO 2006036465 A3 WO2006036465 A3 WO 2006036465A3 US 2005031576 W US2005031576 W US 2005031576W WO 2006036465 A3 WO2006036465 A3 WO 2006036465A3
Authority
WO
WIPO (PCT)
Prior art keywords
cystic fibrosis
compositions
methods
treating cystic
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/031576
Other languages
English (en)
Other versions
WO2006036465A9 (fr
WO2006036465A2 (fr
Inventor
Terrance Robin Flotte
Jeffrey Robert Dvm Sirninger
William B Guggino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
Original Assignee
University of Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida filed Critical University of Florida
Publication of WO2006036465A2 publication Critical patent/WO2006036465A2/fr
Publication of WO2006036465A9 publication Critical patent/WO2006036465A9/fr
Publication of WO2006036465A3 publication Critical patent/WO2006036465A3/fr
Priority to US11/713,291 priority Critical patent/US8137962B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention porte sur des compositions et des méthodes de traitement de la fibrose kystique. Cette invention concerne plus spécifiquement l'utilisation des vecteurs et constructions AAV pour procurer une thérapie génique aux patients atteints de fibrose kystique.
PCT/US2005/031576 2004-09-03 2005-09-02 Compositions et methodes de traitement de la fibrose kystique Ceased WO2006036465A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/713,291 US8137962B2 (en) 2004-09-03 2007-03-02 Compositions for treating cystic fibrosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60732404P 2004-09-03 2004-09-03
US60/607,324 2004-09-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/713,291 Continuation-In-Part US8137962B2 (en) 2004-09-03 2007-03-02 Compositions for treating cystic fibrosis

Publications (3)

Publication Number Publication Date
WO2006036465A2 WO2006036465A2 (fr) 2006-04-06
WO2006036465A9 WO2006036465A9 (fr) 2006-06-29
WO2006036465A3 true WO2006036465A3 (fr) 2006-11-23

Family

ID=36119363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/031576 Ceased WO2006036465A2 (fr) 2004-09-03 2005-09-02 Compositions et methodes de traitement de la fibrose kystique

Country Status (2)

Country Link
US (1) US8137962B2 (fr)
WO (1) WO2006036465A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2561067T3 (en) 2010-04-23 2019-03-11 Univ Florida RAAV-GUANYLAT CYCLE COMPOSITIONS AND PROCEDURES FOR TREATING LEVERS CONGENITAL AMAUROSE-1 (LCA1)
RS63416B1 (sr) 2015-03-03 2022-08-31 Fond Telethon Sistem višestrukih vektora i njegove primene
WO2019070891A1 (fr) 2017-10-03 2019-04-11 Prevail Therapeutics, Inc. Thérapies géniques pour troubles lysosomaux
AU2018346105C1 (en) 2017-10-03 2023-10-12 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
WO2019070893A1 (fr) * 2017-10-03 2019-04-11 Prevail Therapeutics, Inc. Thérapies géniques pour troubles lysosomaux
HRP20231296T1 (hr) 2019-01-18 2024-02-16 Institut Pasteur Genska terapija posredovana s avv koja obnavlja gen za otoferlin
WO2020210698A1 (fr) 2019-04-10 2020-10-15 Prevail Therapeutics, Inc. Thérapies géniques pour troubles lysosomaux
WO2020210713A1 (fr) 2019-04-10 2020-10-15 Prevail Therapeutics, Inc. Thérapies géniques pour troubles lysosomaux
KR20230026985A (ko) 2020-04-27 2023-02-27 4디 몰레큘러 테라퓨틱스 아이엔씨. 폐 전달을 위한 아데노-관련 변이체, 제제 및 방법
CN112575074B (zh) * 2020-10-09 2022-12-27 中山大学 Nestin基因及蛋白在治疗器官纤维化中的应用
EP4262882A1 (fr) 2020-12-18 2023-10-25 Institut Pasteur Thérapie génique pour traiter le syndrome d'usher
EP4398943A1 (fr) 2021-09-10 2024-07-17 Institut Pasteur Système de vecteur aav8 recombinant double codant pour l'isoforme 5 de l'otoferline et ses utilisations
AU2023264251A1 (en) 2022-05-02 2024-12-05 Fondazione Telethon Ets Homology independent targeted integration for gene editing
WO2023213817A1 (fr) 2022-05-02 2023-11-09 Fondazione Telethon Ets Thérapie génique pour l'atrophie gyrate de la choroïde et de la rétine
IT202300004443A1 (it) 2023-03-09 2024-09-09 Int Centre For Genetic Engineering And Biotechnology Icgeb Sequenza codificante per alfa galattosidasi a umana per il trattamento della malattia di fabry
WO2024258925A1 (fr) 2023-06-12 2024-12-19 Children's Hospital Medical Center Vecteurs aav-cftr et leurs procédés d'utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056502B2 (en) * 2000-04-28 2006-06-06 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587308A (en) * 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US6294379B1 (en) * 1998-02-25 2001-09-25 The Regents Of The University Of California Efficient AAV vectors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056502B2 (en) * 2000-04-28 2006-06-06 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AURICCHIO A.: "Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins", J. CLINICAL INVESTIGATION, vol. 110, no. 4, August 2002 (2002-08-01), pages 499 - 504, XP002962742 *
BECK S.E. ET AL.: "Repeated delivery of adeno-associated virus vectors to the rabbit airway", J. VIROLOGY, vol. 73, no. 11, November 1999 (1999-11-01), pages 9446 - 9455, XP003003688 *
KOEHLER D.R. ET AL.: "Protection of Cftr knockout mice from acute lung infection by a helper-dependent adenoviral vector expression Cftr in airway epithelia", PROC. NATL. ACAD. SCI. USA, vol. 100, no. 26, December 2003 (2003-12-01), pages 15364 - 15369, XP003003690 *
MOSS R.B. ET AL.: "Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial", CHEST, vol. 125, no. 2, February 2004 (2004-02-01), pages 509 - 521, XP003003689 *
ZOLOTUKHIN S. ET AL.: "Production and purification of serotype 1,2 and 5 recombinant adeno-associated viral vectors", METHODS, vol. 28, no. 2, October 2002 (2002-10-01), pages 158 - 167, XP002256404 *

Also Published As

Publication number Publication date
US20080003204A1 (en) 2008-01-03
WO2006036465A9 (fr) 2006-06-29
US8137962B2 (en) 2012-03-20
WO2006036465A2 (fr) 2006-04-06

Similar Documents

Publication Publication Date Title
WO2006036465A3 (fr) Compositions et methodes de traitement de la fibrose kystique
WO2001083729A3 (fr) Vecteurs pour transduction oculaire et utilisation en therapie genique
WO2001097829A3 (fr) Traitement de substitution enzymatique, therapie genique et therapie par petites molecules pour maladies liees au stockage lysosomal
WO2008106646A3 (fr) Procédés et formulations pour une thérapie génique topique
WO2005062881A3 (fr) Therapie genique faisant intervenir des vecteurs de transposon
WO2006023544A3 (fr) Applications therapeutiques d'inhibiteurs de rtp801
WO2003012057A3 (fr) Modulation antisens de l'expression du serum amyloide a4
WO2004030750A8 (fr) Modulation antisens de l'expression du fxr (farnesoid x receptor)
WO2002092772A3 (fr) Modulation antisens de l'expression de ptp1b
WO2007021982A3 (fr) Modulateurs du regulateur de la conductance transmembranaire de la fibrose kystique
WO2004069156A3 (fr) Bacteries probiotiques inactivees et leurs procedes d'utilisation
WO2007011962A3 (fr) Traitement du cancer
WO2004044181A3 (fr) Modulation antisens de l'expression d'apolipoproteine b
WO2007024708A3 (fr) Arn contenant des nucleosides modifies, et procedes d'utilisation associes
WO2007084684A3 (fr) Utilisations therapeutiques d’inhibiteurs de rtp801
WO2003097662A8 (fr) Modulation antisens de l'expression de l'apolipoproteine b
WO2005091853A3 (fr) Procedes et compositions pour traiter des pathologies associees a l'il-13
WO2003010284A3 (fr) Modulation antisens de l'expression de la proteine reactive c
WO2007035771A3 (fr) Modulation de l'expression du recepteur du glucagon
WO2003046132A3 (fr) Modulation antisens de l'expression du myd88
WO2003022222A3 (fr) Modulation anti-sens de l'expression d'une proteine kinase r
WO2005014607A3 (fr) Modulation antisens de l'expression de la stearoyl-coa desaturase
WO2005000208A3 (fr) Therapie combinee pour le traitement des neoplasmes
WO2007124148A3 (fr) Traitement de troubles du tissu conjonctif
WO2002095053A3 (fr) Modulation antisens de l'expression des src-c

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/27-27/27, DRAWINGS, REPLACED BY CORRECT PAGES 1/27-27/27

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11713291

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 11713291

Country of ref document: US